2021 Year in Review - Breast Cancer

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

Breast Cancer

A Subanalysis of the Phase 3 MONARCH 3 Study of Abemaciclib as Initial Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer

Effectiveness of Alpelisib plus Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR-Positive, HER2-Negative, PIK3CA Mutation–Positive Breast Cancer

Breast Cancer

Updates on Endocrine Therapy for Metastatic Breast Cancer

Breast Cancer

Patient-Reported Outcomes from a Phase 3 Trial in Premenopausal Patients with ER-Positive, HER2-Negative, Lymph Node–Positive Breast Cancer

Breast Cancer

Checkpoint Inhibitor Therapy for Metastatic Triple-Negative Breast Cancer

Breast Cancer

Emerging Immunotherapy Combination Strategies for Breast Cancer: Dual Immune Checkpoint Modulation, Antibody–Drug Conjugates, and Bispecific Antibodies

Breast Cancer

Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: An Overview of Clinical Management and Potential Toxicities

Breast Cancer

SASCIA Phase 3 Trial Evaluating Sacituzumab Govitecan in Patients with Primary HER2-Negative Breast Cancer with High Relapse Risk

Breast Cancer

Trastuzumab Deruxtecan Granted Breakthrough Therapy Designation in United States for Patients with HER2-Positive Metastatic Breast Cancer Treated with ≥1 Previous Anti-HER2–Based Regimens

Breast Cancer

New Antibody–Drug Conjugates in Breast Cancer

Page 1 of 3
Results 1 - 10 of 28